Sales of the Genmab-developed bone marrow cancer drug, Darzalex, which Johnson & Johnson has licensed, surpassed projections for the first quarter of 2022, as revealed by Johnson & Johnson’s financial report on Tuesday.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
WS Audiology lives up to topline growth expectations – sees challenges ahead
The hearing giant reported 7% organic revenue growth for the financial year, though macroeconomic conditions have led the firm to be more conservative with next year’s estimates.
WS Audiology CEO expects market slowdown to continue in coming months
The hearing aid manufacturer is expecting growth in fiscal 2022/2023 to be under its recent annual result due to a market decline that looks to continue into the future, says CEO Eric Bernard.
Bavarian Nordic grants all employees an extra four days off
After a busy year at the Danish drugmaker, the firm has decided to give something back to its workers in the shape of four days extra vacation time.
Bank believes in cancer approval for Genmab
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
WSA CEO says Kirkland Signature absence at Costco has helped
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.
Head of Engineering 
Quality Compliance Specialist - Herbal Medicines and Medical Devices 
Chief consultant for Dansk Erhvervs Health and life science 
Research Scientist (maternity cover) 
Principal Test Engineer 
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Regulatory Affairs Manager 
Department Manager for Chemistry & Radiochemistry at Minerva Imaging 
New Product Introduction Manager Nordics 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Supply Chain Manager